Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash from Investing Activities (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cash from Investing Activities for 11 consecutive years, with $775000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 96.73% to $775000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $47.5 million, a 149.26% increase, with the full-year FY2025 number at $47.5 million, up 149.26% from a year prior.
  • Cash from Investing Activities was $775000.0 for Q4 2025 at Iovance Biotherapeutics, down from $17.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $153.4 million in Q1 2023 to a low of -$156.8 million in Q2 2023.
  • A 3-year average of -$17.0 million and a median of $7.3 million in 2025 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 172.69% in 2024, then soared 134.86% in 2025.
  • Iovance Biotherapeutics' Cash from Investing Activities stood at -$72.8 million in 2023, then skyrocketed by 132.5% to $23.7 million in 2024, then tumbled by 96.73% to $775000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cash from Investing Activities are $775000.0 (Q4 2025), $17.0 million (Q3 2025), and $13.8 million (Q2 2025).